These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23353592)

  • 21. Drug-drug interaction potential of the HBV and HDV entry inhibitor myrcludex B assessed in vitro.
    Blank A; Meier K; Urban S; Haefeli WE; Weiss J
    Antivir Ther; 2018; 23(3):267-275. PubMed ID: 29134945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Obatoclax as a perpetrator in drug-drug interactions and its efficacy in multidrug resistance cell lines.
    Theile D; Allendorf D; Köhler BC; Jassowicz A; Weiss J
    J Pharm Pharmacol; 2015 Nov; 67(11):1575-84. PubMed ID: 26255619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
    Sidharta PN; Krähenbühl S; Dingemanse J
    Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):437-49. PubMed ID: 25604973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro.
    Theile D; Haefeli WE; Weiss J
    Endocrine; 2015 Aug; 49(3):842-53. PubMed ID: 25542188
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist.
    Iglarz M; Binkert C; Morrison K; Fischli W; Gatfield J; Treiber A; Weller T; Bolli MH; Boss C; Buchmann S; Capeleto B; Hess P; Qiu C; Clozel M
    J Pharmacol Exp Ther; 2008 Dec; 327(3):736-45. PubMed ID: 18780830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects.
    Sidharta PN; van Giersbergen PL; Dingemanse J
    J Clin Pharmacol; 2013 Nov; 53(11):1131-8. PubMed ID: 23900878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension.
    Iglarz M; Landskroner K; Bauer Y; Vercauteren M; Rey M; Renault B; Studer R; Vezzali E; Freti D; Hadana H; Schläpfer M; Cattaneo C; Bortolamiol C; Weber E; Whitby BR; Delahaye S; Wanner D; Steiner P; Nayler O; Hess P; Clozel M
    J Cardiovasc Pharmacol; 2015 Nov; 66(5):457-67. PubMed ID: 26230396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The new endothelin receptor antagonist macitentan: Prospects for therapy of pulmonary arterial hypertension].
    Avdeev SN
    Ter Arkh; 2016; 88(7):89-97. PubMed ID: 27459621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination Therapy of Pulmonary Arterial Hypertension with Vardenafil and Macitentan Assessed in a Human Ex Vivo Model.
    Hoenicka M; Golovchenko S; Englert L; Spaeth M; Shoshiashvili L; Großer C; Hofmann HS; Ried M
    Cardiovasc Drugs Ther; 2019 Jun; 33(3):287-295. PubMed ID: 30826900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel dual endothelin receptor antagonist macitentan reverses severe pulmonary arterial hypertension in rats.
    Kunita-Takanezawa M; Abe K; Hirooka Y; Kuwabara Y; Hirano K; Oka M; Sunagawa K
    J Cardiovasc Pharmacol; 2014 Nov; 64(5):473-80. PubMed ID: 25084082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic-pharmacodynamic relationships of macitentan, a new endothelin receptor antagonist, after multiple dosing in healthy Korean subjects.
    Ahn LY; Kim SE; Yi S; Dingemanse J; Lim KS; Jang IJ; Yu KS
    Am J Cardiovasc Drugs; 2014 Oct; 14(5):377-85. PubMed ID: 24906252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.
    Dingemanse J; van Giersbergen PL
    Clin Pharmacokinet; 2004; 43(15):1089-115. PubMed ID: 15568889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects.
    Sidharta PN; van Giersbergen PL; Wolzt M; Dingemanse J
    Br J Clin Pharmacol; 2014 Nov; 78(5):1035-42. PubMed ID: 24962473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions.
    Weiss J; Bajraktari-Sylejmani G; Haefeli WE
    Chem Biol Interact; 2021 Apr; 338():109428. PubMed ID: 33647240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptor.
    van Giersbergen PL; Gnerre C; Treiber A; Dingemanse J; Meyer UA
    Eur J Pharmacol; 2002 Aug; 450(2):115-21. PubMed ID: 12206849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Macitentan: entry-into-humans study with a new endothelin receptor antagonist.
    Sidharta PN; van Giersbergen PL; Halabi A; Dingemanse J
    Eur J Clin Pharmacol; 2011 Oct; 67(10):977-84. PubMed ID: 21541781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Macitentan blocks endothelin-1 receptor activation required for chemoresistant ovarian cancer cell plasticity and metastasis.
    Sestito R; Cianfrocca R; Rosanò L; Tocci P; Di Castro V; Caprara V; Bagnato A
    Life Sci; 2016 Aug; 159():43-48. PubMed ID: 26776834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice.
    Kim SJ; Lee HJ; Kim MS; Choi HJ; He J; Wu Q; Aldape K; Weinberg JS; Yung WK; Conrad CA; Langley RR; Lehembre F; Regenass U; Fidler IJ
    Clin Cancer Res; 2015 Oct; 21(20):4630-41. PubMed ID: 26106074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The potential of Sutherlandia frutescens for herb-drug interaction.
    Fasinu PS; Gutmann H; Schiller H; James AD; Bouic PJ; Rosenkranz B
    Drug Metab Dispos; 2013 Feb; 41(2):488-97. PubMed ID: 23209194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
    Dingemanse J; Sidharta PN; Maddrey WC; Rubin LJ; Mickail H
    Expert Opin Drug Saf; 2014 Mar; 13(3):391-405. PubMed ID: 24261583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.